Money Matters - Simplified

What Investors Think About Biogen Idec

Together, we are all trying to build our fortune by finding well-run companies at bargain-basement prices. But it takes work -- scouring company earnings reports, scrutinizing key data, and assessing the competition.

Because of that, we've created a screen based on the massive data aggregated from the more than 165,000 investors competing on our Motley Fool CAPS platform. Each quarter, we check in on select companies after they file a 10-Q and track community sentiment -- so you can see how your company is doing.

Here's the community sentiment on Biogen Idec (Nasdaq: BIIB) both this quarter and last (for comparison), as well as opinions on some related companies.

Metric Biogen Idec Opko Health(AMEX:OPK) Acorda Therapeutics(Nasdaq: ACOR) Lexicon Pharmaceuticals(Nasdaq: LXRX)
This Quarter (7/20/2010):
Price: $54.02 $2.34 $31.14 $1.33
% of Members Rating Outperform 92% 86% 63% 93%
% of All-Star Members Rating Outperform 96% 84% 47% 92%
CAPS Rating (out of 5) *** ** * ****
Last Quarter (4/21/2010):
Price: $52.72 $2.29 $38.22 $1.55
% of Members Rating Outperform 93% 86% 64% 93%
% of All-Star Members Rating Outperform 95% 90% 50% 94%
CAPS Rating (out of 5) *** *** * *****

Source: Motley Fool CAPS. Dates given are the posting dates of Biogen Idec's most recent quarterly and/or annual reports to the SEC's website. Percentages are calculated from the number of members rating each company.

A change in the community's approval (signified by four- and five-star ratings) or disapproval (one- and two-star ratings) could indicate that further research is in order. To help make your research easier …

  • Share any thoughts you have about Biogen Idec -- or any of the other companies mentioned -- in the comments box below.
  • Head over to the completely free CAPS service -- a one-stop research shop -- and read what your fellow investors are saying about your stocks.

© 2010 UCLICK L.L.C